| Singapore-listed specialty pharmaceutical company iX Biopharma said "exceptional demand" has been seen for its LumeniX and RestoriX nutraceutical products less than three weeks into the opening of its Entity flagship stores on JD Worldwide and Tmall Global. Tmall and JD are the two largest e-commerce platforms in China, commanding over 85% of the total B2C e-commerce market in China.  "Initial stock of LumeniX has sold out on Entity’s Tmall Global and JD Worldwide stores, and RestoriX is sold out on its JD Worldwide store, ahead of initial forecasts provided by its marketing agencies in China." Entity’s leading beauty supplement, LumeniX, is a novel sublingual wafer containing glutathione, the master of all antioxidants, formulated using iX Biopharma’s WaferiX drug delivery technology. |
• LumeniX is a dual-purpose supplement designed to promote skin fairness, while helping the body to build a stronger immunity against viral infections.
Glutathione is normally effective for skin brightening when given intravenously in clinics by trained healthcare workers.
Through the use of WaferiX, a delivery technology clinically proven to increase absorption and bioavailability of active ingredients, an effective glutathione product is now available to the mass consumer market. 
• RestoriX is a nicotinamide supplement designed to boost NAD (nicotinamide adenine dinucleotide) levels in the body.
NAD is a molecule that Harvard Medical School geneticists have studied in recent years for its ability to switch off ‘ageing’ genes.
RestoriX aims to counter the process of ageing and increase health span, while boosting energy levels and vitality.
 Ms Eva Tan (photo), Director of Corporate and Commercial Strategy of iX Biopharma, said: “We are very encouraged to have received such strong support from Chinese consumers during our store launches. We observed that the Chinese consumers are purchasing LumeniX not only because it is a novel beauty product, but they are also responding to LumeniX’s ability to boost the body’s immune system, which can help to protect against viral infections. "Overall we are delighted by the quick take-up of LumeniX and RestoriX, which reflects the strong demand by Chinese consumers for innovative, functional nutraceuticals that characterise the Entity line of products.” |
|
Stock price |
27 c |
|
52-week range |
13 – 34 c |
|
Market cap |
S$172 m |
|
PE (ttm) |
- |
|
Dividend yield |
- |
|
1-year return |
21% |
|
Shares outstanding |
649 m |
|
Source: Bloomberg |
|
Both stores will be restocked shortly to meet the growing demand, said iX Biopharma.
"At the rate of the initial response, plus the growth projected by the agencies, Entity will hit its wafer production capacity very soon.
"The iX Biopharma group has invested in new equipment which will significantly increase its wafer production capacity."
